Sclerodermatous chronic graft-versus-host disease (cGVHD) following allogeneic
hematopoietic stem cell transplantation (HSCT) in children is difficult to treat and life …

Methods. Using standard apheresis procedure, 300 mL of plasma and 240 mL of buffy coat
were collected and diluted with 200 mL of saline. The enriched lymphocyte solution was …

Graft-versus-host disease (GVHD) is defined by the aggregation of clinical and pathological
manifestations in a recipient of allogeneic stem cells or bone marrow transplantation in …

Background Extracorporeal photopheresis (ECP) is an important cell‐based therapy for graft‐
versus‐host disease (GVHD); however, the blood volume required per treatment to achieve …

Case# 2. A 5-year old boy, transplanted in 1992 for Fanconi's anemia from his HLA-identical
brother, developed progressive extensive cGvHD, barely controlled by standard …

Background and objectives Extracorporeal photopheresis (ECP) is a treatment strategy in
steroid-refractory chronic graft-versus-host disease (cGvHD). In this study, we aimed to …

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following
allogeneic stem cell transplantation (ASCT). Extracorporeal photopheresis (ECP) has been …

Objectives Chronic graft versus host disease (chronic GVHD) still remains the leading cause
of late morbidity and mortality for allogeneic hematopoietic stem cell transplant (allo-HSCT) …

Extracorporeal photoimmunochemotherapy (ECP, photopheresis) was introduced in 1987
for the palliative management of cutaneous T-cell lymphoma (CTCL)[1]. ECP was shown to …

BACKGROUND AND OBJECTIVES: Standard or investigative immunosuppressive
therapies for cutaneous chronic graft-versus-host disease (GVHD) may prove not only …